Date: 2014-01-09
Type of information: Series D financing round
Company: AC Immune (Switzerland)
Investors:
Amount: CHF 20 million (€16.1 million)
Funding type: series D financing round
Planned used: The new funds, along with existing cash resources, will enable AC Immune to further advance its clinical and pre-clinical drug pipeline. These resources will mainly support the newly initiated groundbreaking clinical trial of the anti-pTau vaccine ACI-35.
Others: * On January 9, 2014, AC Immune has announced it has successfully completed its round D financing by raising CHF 20 million from current private investors. The company also announced it has started the world’s first trial of a vaccine against the phospho-Tau target for Alzheimer’s disease.
The successful financing of CHF 20 million was fully subscribed by existing private investors who have now committed a total of CHF 84 million in four rounds since AC Immune was founded in 2003. The company will call on the latest funds in two tranches according to its financial requirements.
Therapeutic area: Neurodegenerative diseases
